Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial

Parker, C., Finkelstein, S.E., Michalski, J.M. et al. (9 more authors) (2016) Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial. European Urology, 70 (5). pp. 875-883. ISSN 0302-2838

Abstract

Metadata

Authors/Creators:
  • Parker, C.
  • Finkelstein, S.E.
  • Michalski, J.M.
  • O'Sullivan, J.M.
  • Bruland, Ø.
  • Vogelzang, N.J.
  • Coleman, R.E. https://orcid.org/0000-0002-4275-1043
  • Nilsson, S.
  • Sartor, O.
  • Li, R.
  • Seger, M.A.
  • Bottomley, D.
Copyright, Publisher and Additional Information: © 2016 European Association of Urology. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords: ALSYMPCA; Analgesics; Bone metastases; Bone pain; Castration-resistant prostate; cancer; External beam radiation therapy; Opioids; Radium-223 dichloride; Skeletal metastases; Symptomatic
Dates:
  • Published: November 2016
  • Accepted: 3 June 2016
  • Published (online): 22 June 2016
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Medicine (Sheffield) > Division of Genomic Medicine (Sheffield) > Department of Oncology (Sheffield)
The University of Sheffield > Sheffield Teaching Hospitals
Depositing User: Symplectic Sheffield
Date Deposited: 13 Jul 2016 10:30
Last Modified: 18 Jul 2017 10:37
Published Version: http://dx.doi.org/10.1016/j.eururo.2016.06.002
Status: Published
Publisher: Elsevier
Refereed: Yes
Identification Number: https://doi.org/10.1016/j.eururo.2016.06.002

Share / Export

Statistics